Summary
DexCom, Inc. reported its financial results for the first quarter ended March 31, 2011. The company, a medical device firm focused on continuous glucose monitoring (CGM) systems, continued to experience revenue growth in its product segment, with product revenue increasing to $13.1 million from $6.8 million in the prior year's comparable quarter. This growth was driven by higher sales volumes and improved average selling prices for its durable systems and disposable sensors. However, the company also saw a decrease in development grant and other revenues, largely due to extended development and regulatory timelines with partners like Edwards and Animas. Despite the revenue increase, DexCom reported an operating loss and a net loss for the quarter. The company's R&D expenses rose due to increased development efforts for future products, and SG&A expenses also increased to support growth. Management remains focused on commercialization efforts for its SEVEN PLUS system and further product development, anticipating continued losses in the near future. The company believes its current liquidity position is sufficient to fund operations through at least March 31, 2012, but acknowledges the potential need for future financing.
Financial Highlights
25 data points| Revenue | $14.20M |
| Cost of Revenue | $9.06M |
| Gross Profit | $5.10M |
| R&D Expenses | $6.27M |
| SG&A Expenses | $10.72M |
| Operating Expenses | $17.00M |
| Operating Income | -$11.87M |
| Interest Expense | $6K |
| Net Income | -$11.80M |
| EPS (Basic) | $-0.05 |
Key Highlights
- 1Product revenue increased significantly to $13.1 million for Q1 2011, up from $6.8 million in Q1 2010, primarily due to higher sales volume and prices.
- 2The company reported a net loss of $11.9 million for Q1 2011, an improvement from a net loss of $20.3 million in Q1 2010, largely due to a significant decrease in interest expense related to the conversion of convertible debt.
- 3Operating expenses increased, with Research & Development up to $6.3 million from $4.7 million and Selling, General & Administrative expenses up to $10.7 million from $9.8 million, reflecting investment in future products and sales support.
- 4Cash used in operating activities decreased slightly to $9.3 million from $10.4 million, though the company continues to burn cash.
- 5The company's cash and cash equivalents, along with short-term marketable securities, totaled $37.3 million, providing an estimated runway of over one year for operations.
- 6DexCom is actively involved in patent litigation with Abbott Diabetes Care, which remains a significant ongoing legal and financial concern.
- 7Development grant and other revenue decreased to $1.0 million from $2.8 million, attributed to extended development and regulatory review timelines with partners.